Clinical Trial

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-09-03; most recent amendment 2026-03-23.
Status change: Active, Not Recruiting → Recruiting 2025-10-21
Status change: Recruiting → Active, Not Recruiting 2025-03-16
Status change: Not Yet Recruiting → Recruiting 2024-09-17
Trial Details
NCT Number NCT06585241
Lead Sponsor ModernaTX, Inc.
Conditions SARS-CoV-2
Enrollment 1,144 participants
Start Date 2024-09-09
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27